首页|六味地黄丸合二至丸组方联合西医常规治疗对早期糖尿病肾病(肝肾阴虚证)患者的临床疗效观察

六味地黄丸合二至丸组方联合西医常规治疗对早期糖尿病肾病(肝肾阴虚证)患者的临床疗效观察

扫码查看
目的:探讨六味地黄丸合二至丸组方联合恩格列净片、缬沙坦片对早期糖尿病肾病(肝肾阴虚证)患者的疗效及对血糖指标、肾功能、血清单核细胞趋化蛋白-1(MCP-1)、转化生长因子-β1(TGF-β1)和炎症因子的影响。方法:选取2020年9月至2023年2月该院收治的早期糖尿病肾病(肝肾阴虚证)患者128例,按随机数字表法分为对照组与观察组,各64例。两组患者均给予健康教育和饮食指导,在此基础上,对照组患者口服恩格列净片和缬沙坦片,观察组患者在对照组的基础上联合六味地黄丸合二至丸组方治疗,共治疗8周。评估临床疗效和不良反应发生情况,检测治疗前后两组患者的血糖指标[空腹血糖(FBG)、糖化血红蛋白(HbA1c)]、肾功能指标[尿素氮(BUN)、血肌酐(SCr)和尿白蛋白排泄率(UAER)]、血清MCP-1、TGF-β1和炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)]水平。结果:观察组患者的总有效率为93。75%(60/64),较对照组(81。25%,52/64)更高,差异有统计学意义(P<0。05)。治疗后,两组患者的 FBG、HbA1c、BUN、SCr、UAER、MCP-1、TGF-β1、TNF-α 和 IL-1β水平均较治疗前显著降低,且观察组患者的FBG、HbA1c、BUN、SCr、UAER、MCP-1、TGF-β1、TNF-α和IL-1β水平较对照组更低,差异均有统计学意义(P<0。05)。对照组、观察组患者的总不良反应发生率分别为12。50%(8/64)、14。06%(9/64),差异无统计学意义(P>0。05)。结论:六味地黄丸合二至丸组方联合恩格列净片、缬沙坦片可有效改善早期糖尿病肾病(肝肾阴虚证)患者的血糖、肾功能指标、MCP-1、TGF-β1及炎症因子水平,提高临床疗效,且安全性较好。
Clinical Efficacy of Liuwei Dihuang Pills and Erzhi Pills Prescription Combined with Conventional Western Medicine in the Treatment of Patients with Early Diabetic Nephropathy(Liver-Kidney Yin Deficiency Syndrome)
OBJECTIVE:To probe into the efficacy of Liuwei Dihuang pills and Erzhi pills combined with Empagliflozin tablets and Valsartan tablets in the treatment of patients with early diabetic nephropathy(liver-kidney Yin deficiency syndrome)and the effects on blood glucose indicator,kidney function,serum monocyte chemotactic protein-1(MCP-1),transforming growth factor-β1(TGF-β1)and inflammatory factors.METHODS:A total of 128 patients with DN(early liver-kidney yin deficiency syndrome)in this hospital from Sept.2020 to Feb.2023 were extracted to be divided into control group and observation group via the random number table method,with 64 cases in each group.Two groups were given health education and dietary guidance,on the basis of which the control group was given oral treatment of Empagliflozin tablets and Valsartan tablets,the observation group received Liuwei Dihuang pills and Erzhi pills prescription on the basis of the control group,with 8 weeks of total treatment.Clinical efficacy and occurrence of adverse drug reactions were evaluated.Blood glucose indicators[fasting blood glucose(FBG),glycated hemoglobin(HbA1c)],renal function[blood urea nitrogen(BUN),serum creatinine(SCr),urinary albumin excretion rate(UAER)],serum MCP-1,TGF-β1,inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1 β)]levels were detected before and after treatment.RESULTS:The total effective rate of observation group was 93.75%(60/64),higher than 81.25%(52/64)of control group,with statistically significant difference(P<0.05).After treatment,the levels of FBG,HbA1c,BUN,SCr,UAER,MCP-1,TGF-β1,TNF-αand IL-1 β in both groups decreased significantly compared with those before treatment,the levels of FBG,HbA1c,BUN,SCr,UAER,MCP-1,TGF-β1,TNF-α and IL-1 β in observation group were lower than those in control group,with statistically significant differences(P<0.05).The total incidence of adverse drug reactions in control group and observation group was respectively 12.50%(8/64)and 14.06%(9/64),with no statistical significance(P>0.05).CONCLUSIONS:Liuwei Dihuang pills and Erzhi pills combined with Empagliflozin tablets and Valsartan tablets can effectively improve the levels of blood glucose,renal function indicators,MCP-1,TGF-β1 and inflammatory factors in patients with early DN(liver-kidney Yin deficiency syndrome),and promote clinical efficacy with higher safety.

Liuwei Dihuang pills and Erzhi pills prescriptionEmpagliflozin tabletsValsartan tabletsLiver-kidney Yin deficiency syndromeDiabetic nephropathy

张政赢、鞠阳、刘晓宁、江冉冉、庞坤、王竞、路露、王晶、仝超

展开 >

华北医疗健康集团峰峰总医院药剂科,河北邯郸 056200

华北医疗健康集团峰峰总医院内科,河北邯郸 056200

华北医疗健康集团峰峰总医院检验科,河北邯郸 056200

六味地黄丸合二至丸组方 恩格列净片 缬沙坦片 肝肾阴虚证 糖尿病肾病

河北省中医药类科研计划项目邯郸市科学技术研究与发展计划项目

202146919422083012-7

2024

中国医院用药评价与分析
中国医药生物技术协会,中国药房杂志社

中国医院用药评价与分析

CSTPCD
影响因子:1.142
ISSN:1672-2124
年,卷(期):2024.24(1)
  • 23